1 gen 2014 anni - Pembrolizumab
Descrizione:
Pembrolizumab is approved for advanced melanoma treatment by the FDA. This monoclonal antibody blocks a protein called PD1's activity on immune cells, which increases the strength of the immune response to cancer.
Aggiunto al nastro di tempo:
Data: